{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:44:38Z","timestamp":1792698278592,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006254","name":"Ruhr-Universit\u00e4t Bochum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006254","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The PASCAL system is a novel device for edge-to-edge treatment of mitral regurgitation (MR). The aim of this study was to compare the safety and efficacy of the PASCAL to the MitraClip system in a highly selected group of patients with complex primary mitral regurgitation (PMR) defined as effective regurgitant orifice area (MR-EROA)\u2009\u2265\u20090.40 cm<jats:sup>2<\/jats:sup>, large flail gap (\u2265\u20095\u00a0mm) or width (\u2265\u20097\u00a0mm) or Barlow\u2019s disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>38 patients with complex PMR undergoing mitral intervention using PASCAL (<jats:italic>n<\/jats:italic>\u2009=\u200922) or MitraClip (<jats:italic>n<\/jats:italic>\u2009=\u200916) were enrolled. Primary efficacy endpoints were procedural success and degree of residual MR at discharge. The rate of major adverse events (MAE) according to the Mitral Valve Academic Consortium (MVARC) criteria was chosen as the primary safety endpoint.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patient collectives did not differ relevantly regarding pertinent baseline parameters. Patients` median age was 83.0 [77.5\u201385.3] years (PASCAL) and 82.5 [76.5\u201386.5] years (MitraClip). MR-EROA at baseline was 0.70 [0.68\u20130.83] cm<jats:sup>2<\/jats:sup> (PASCAL) and 0.70 [0.50\u20130.90] cm<jats:sup>2<\/jats:sup> (MitraClip), respectively. 3D-echocardiographic morphometry of the mitral valve apparatus revealed no relevant differences between groups. Procedural success was achieved in 95.5% (PASCAL) and 87.5% (MitraClip), respectively. In 86.4% of the patients a residual MR grade\u2009\u2264\u20091\u2009+\u2009was achieved with PASCAL whereas reduction to MR grade\u2009\u2264\u20091\u2009+\u2009with MitraClip was achieved in 62.5%. Neither procedure time number of implanted devices, nor transmitral gradient differed significantly. No periprocedural MAE according to MVARC occured.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this highly selected patient group with complex PMR both systems exhibited equal procedural safety. MitraClip and PASCAL reduced qualitative and semi-quantitative parameters of MR to an at least comparable extent.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphic abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00392-021-01845-8","type":"journal-article","created":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T03:28:20Z","timestamp":1618025300000},"page":"1890-1899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["PASCAL mitral valve repair system versus MitraClip: comparison of transcatheter edge-to-edge strategies in complex primary mitral regurgitation"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1822-936X","authenticated-orcid":false,"given":"Muhammed","family":"Ger\u00e7ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1029-2185","authenticated-orcid":false,"given":"Fabian","family":"Roder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8839-7476","authenticated-orcid":false,"given":"Tanja K.","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Fortmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Zittermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai P.","family":"Friedrichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,10]]},"reference":[{"issue":"25","key":"1845_CR1","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1016\/j.jacc.2015.10.018","volume":"66","author":"T Feldman","year":"2015","unstructured":"Feldman T, Kar S, Elmariah S et al (2015) Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol 66(25):2844\u20132854. https:\/\/doi.org\/10.1016\/j.jacc.2015.10.018","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"1845_CR2","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38(36):2739\u20132791. https:\/\/doi.org\/10.1093\/eurheartj\/ehx391","journal-title":"Eur Heart J"},{"key":"1845_CR3","unstructured":"Lim DS (2020) EXPAND: Next-generation MitraClip NTR, XTR safe, effective for primary MR patients. ACC.20\/WCC, abstract 412\u201312.2020"},{"issue":"10096","key":"1845_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/s0140-6736(17)31600-8","volume":"390","author":"F Praz","year":"2017","unstructured":"Praz F, Spargias K, Chrissoheris M et al (2017) Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet (London, England) 390(10096):773\u2013780. https:\/\/doi.org\/10.1016\/s0140-6736(17)31600-8","journal-title":"Lancet (London, England)"},{"key":"1845_CR5","doi-asserted-by":"crossref","unstructured":"Mauri V, Besler C, Riebisch M, et al (2020) German Multicenter Experience with a New Leaflet-Based Transcatheter Mitral Valve Repair System for Mitral Regurgitation. JACC Cardiovasc Interv 2020 accepted for publication","DOI":"10.1016\/j.jcin.2020.08.025"},{"issue":"17","key":"1845_CR6","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/j.jacc.2020.02.005","volume":"75","author":"RO Bonow","year":"2020","unstructured":"Bonow RO, O\u2019Gara PT, Adams DH et al (2020) 2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 75(17):2236\u20132270. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.005","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1845_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.21037\/cdt.2017.03.12","volume":"7","author":"ZB Popovi\u0107","year":"2017","unstructured":"Popovi\u0107 ZB, Thomas JD (2017) Assessing observer variability: a user\u2019s guide. Cardiovasc Diagn Ther 7(3):317\u2013324. https:\/\/doi.org\/10.21037\/cdt.2017.03.12","journal-title":"Cardiovasc Diagn Ther"},{"issue":"3","key":"1845_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jacc.2015.05.049","volume":"66","author":"GW Stone","year":"2015","unstructured":"Stone GW, Adams DH, Abraham WT et al (2015) Clinical Trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: a consensus document from the mitral valve academic research consortium. J Am Coll Cardiol 66(3):308\u2013321. https:\/\/doi.org\/10.1016\/j.jacc.2015.05.049","journal-title":"J Am Coll Cardiol"},{"key":"1845_CR9","volume-title":"A unified approach to measuring the effect size between two groups using SAS\u00ae","year":"2012","unstructured":"Yang D, Dalton JE (eds) (2012) A unified approach to measuring the effect size between two groups using SAS\u00ae. SAS global forum"},{"issue":"4","key":"1845_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jcin.2013.12.198","volume":"7","author":"E Lubos","year":"2014","unstructured":"Lubos E, Schl\u00fcter M, Vettorazzi E et al (2014) MitraClip therapy in surgical high-risk patients: identification of echocardiographic variables affecting acute procedural outcome. JACC Cardiovasc Interv 7(4):394\u2013402. https:\/\/doi.org\/10.1016\/j.jcin.2013.12.198","journal-title":"JACC Cardiovasc Interv"},{"key":"1845_CR11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.ijcard.2016.10.054","volume":"227","author":"H Kaneko","year":"2017","unstructured":"Kaneko H, Neuss M, Weissenborn J, Butter C (2017) Impact of residual mitral regurgitation after MitraClip implantation. Int J Cardiol 227:813\u2013819. https:\/\/doi.org\/10.1016\/j.ijcard.2016.10.054","journal-title":"Int J Cardiol"},{"issue":"1","key":"1845_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jtcvs.2015.09.099","volume":"151","author":"N Buzzatti","year":"2016","unstructured":"Buzzatti N, De Bonis M, Denti P et al (2016) What is a \u201cgood\u201d result after transcatheter mitral repair? Impact of 2+ residual mitral regurgitation. J Thorac Cardiovasc Surg 151(1):88\u201396. https:\/\/doi.org\/10.1016\/j.jtcvs.2015.09.099","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"1845_CR13","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.athoracsur.2019.07.014","volume":"109","author":"TMF Watt","year":"2020","unstructured":"Watt TMF, Brescia AA, Murray SL et al (2020) degenerative mitral valve repair restores life expectancy. Ann Thorac Surg 109(3):794\u2013801. https:\/\/doi.org\/10.1016\/j.athoracsur.2019.07.014","journal-title":"Ann Thorac Surg"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01845-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-021-01845-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01845-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T12:05:32Z","timestamp":1638446732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-021-01845-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,10]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1845"],"URL":"https:\/\/doi.org\/10.1007\/s00392-021-01845-8","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,10]]},"assertion":[{"value":"13 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Volker Rudolph and Tanja K. Rudolph have received research grants and speaker honoraria from Edwards Lifesciences Services (Unterschlei\u00dfheim, Germany) and Abbott Vascular. The other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}